• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-22

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its drug-screening and combination-treatment data support evaluating ATRX status when interpreting RTK inhibitor trials and when designing temozolomide-based treatment studies.

• Poria Cocos, NRF2, and Ferroptosis in ALD

  2026-09-22

  The reference study identifies a mechanistic link between Poria cocos polysaccharides, NRF2-dependent redox control, and ferroptosis in alcoholic liver disease. By combining animal and cell models with ML385 and ferrostatin-1 interventions, it suggests that oxidative stress and iron handling are actionable components of alcohol-related liver injury.

• 3-Aminobenzamide: PARP Signaling in Translation

  2026-09-21

  A mechanistic and strategic guide to using 3-Aminobenzamide (PARP-IN-1) to interrogate oxidative stress, vascular dysfunction, diabetic nephropathy, and PARP-linked innate immunity while maintaining translational discipline.

• Calpain Inhibitor II, ALLM: Assay Logic for FAK

  2026-09-21

  Calpain Inhibitor II, ALLM enables a time-resolved strategy for separating calpain–FAK proteolysis from downstream apoptosis. This article translates recent TNBC findings into practical protease inhibition assay decisions while preserving the compound’s important calpain–cathepsin selectivity limits.

• Benzyl Quinolone Carboxylic Acid for M1 Assays

  2026-09-20

  Benzyl Quinolone Carboxylic Acid (BQCA) enables controlled amplification of acetylcholine responses while preserving the opportunity to measure M1 receptor signaling bias. This guide translates its allosteric pharmacology into practical BRET, cellular signaling, neuronal activity, and Alzheimer’s disease research workflows.

• MitMAB: A Mechanistic Lens for EV Uptake

  2026-09-19

  MitMAB provides a focused way to test dynamin-dependent vesicle uptake in physiologically relevant intestinal models. This article connects the compound’s mechanism and handling requirements with polarity-aware milk extracellular vesicle assays, emphasizing causal interpretation rather than simple uptake measurement.

• FK866 (APO866) Workflows for NAMPT Research

  2026-09-19

  FK866 (APO866) enables controlled NAD depletion for mechanistic studies spanning hematologic cancer research and vascular-cell senescence. This practical guide connects dose design, metabolic readouts, mitochondrial assays, and troubleshooting to help researchers distinguish target-linked effects from nonspecific toxicity.

• Coronavirus Macrodomains Counter PARP Antiviral Activity

  2026-09-18

  Grunewald et al. showed that coronavirus macrodomains protect viral replication by opposing PARP-dependent ADP-ribosylation and its enhancement of interferon responses. Pharmacologic inhibition and targeted depletion identified PARP12 and PARP14 as important host restriction factors, providing a mechanistic framework for studying coronavirus–host interactions.

• Annexin V-Cy5 Apoptosis Kit: Lab Scenarios

  2026-09-17

  This scenario-driven guide explains how Annexin V-Cy5 Apoptosis Kit, SKU K2005, supports defensible Annexin V apoptosis detection in microscopy and flow cytometry workflows. It connects phosphatidylserine exposure with practical decisions in microglial stress, lysosomal dysfunction, protocol optimization, data interpretation, and product selection.

• Phenacetin Workflows for PK and Metabolism Studies

  2026-09-17

  Phenacetin provides a practical, research-only small-molecule comparator for absorption, metabolism, analytical recovery, and organoid workflows. This guide connects its solvent and stability profile with assay design while showing how to use it responsibly alongside, but not as a substitute for, emerging PDK4 inhibitor studies.

• Berberine hydrochloride Gut–Bone Workflows

  2026-09-17

  Berberine hydrochloride supports practical AMPK, microbiome, tuft-cell, barrier, and osteoimmune assay workflows. This guide translates a new gut–bone mechanism into controlled exposure, multi-omics, and troubleshooting strategies while distinguishing research evidence from clinical claims.

• Measuring Drug Response Beyond Cell Viability

  2026-09-16

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability to clarify whether an anticancer treatment primarily slows proliferation, induces cell death, or does both. This framework emphasizes matched, time-resolved measurements and provides a practical basis for interpreting drug-response data in cancer research.

• How Cancer Drug Response Metrics Shape In Vitro Evidence

  2026-09-15

  Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an in vitro cancer-drug response. Its central implication is practical: assay interpretation improves when researchers measure proliferation and death as separate, time-dependent outcomes rather than treating one viability value as a complete efficacy readout.

• MK-4827 (Niraparib) for PARP Research

  2026-09-15

  Build reproducible PARP-inhibition workflows with MK-4827 (Niraparib), from BRCA-mutant viability assays to DNA damage response profiling. The workflow also translates recent spliceosome findings in hepatocellular carcinoma into practical combination and biomarker experiments.

• Tivozanib (AV-951) Assay Design Guide

  2026-09-14

  This scenario-based guide explains how Tivozanib (AV-951), SKU A2251, can support reproducible cell viability, proliferation, and cytotoxicity workflows. It connects VEGFR signaling pathway inhibition with practical decisions about controls, formulation, exposure time, data interpretation, and supplier selection.

512 records 1/35 page Next 12345 下5页 Last page